Related Experiment Videos
Tc-99m HMPAO to demonstrate diffuse cortical necrosis in vivo
A J McEwan1, F I Jackson, Z Catz
1Department of Nuclear Medicine, Cross Cancer Institute, Edmonton, Alberta, Canada.
Clinical Nuclear Medicine
|March 1, 1991
Summary
Technetium-99m hexamethylpropylene amineoxime (HMPAO) imaging effectively detects diffuse cerebral perfusion deficits. This radiopharmaceutical showed higher sensitivity than CT scans in a patient with rapid dementia and cortical necrosis.
Area of Science:
- Neurology
- Radiopharmaceuticals
- Medical Imaging
Background:
- Technetium-99m hexamethylpropylene amineoxime (HMPAO) is a radiopharmaceutical used to assess cerebral perfusion.
- Previous studies primarily focused on focal deficits like stroke or diffuse deficits in dementia.
Observation:
- A case study involving a patient with a rapid onset of dementia.
- HMPAO imaging revealed diffuse, non-focal loss of cortical perfusion.
Findings:
- Postmortem examination confirmed diffuse cortical necrosis, correlating well with HMPAO imaging findings.
- HMPAO demonstrated superior sensitivity compared to transmission CT in detecting the extent of perfusion deficits.
Implications:
- HMPAO imaging is a sensitive tool for evaluating diffuse cerebral perfusion abnormalities.
- This technique offers valuable insights into the extent of neurological damage in conditions causing rapid cognitive decline.